Genome editing company Intellia Therapeutics said the European Patent Office (EPO) granted a patent broadly covering the CRISPR/Cas9 genome editing technology.
Cambridge, Massachusets-based Intellia said the patent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeutics.
“The patent includes claims covering compositions of the widely adopted CRISPR single guide RNA technology for use in any non-cellular and cellular setting, including eukaryotic cells such as human or mammalian cells, as well as for use in human therapeutics,” said Intellia.
“According to the EPO, the patent will formally grant on May 10, 2017.
“The EPO’s decision to grant this patent follows its March 24, 2017 notice of intent to issue the patent, which was not challenged by any third party.
“This European patent will be nationalized in, and cover, approximately forty European countries, including Germany, Italy, France, Spain and the Netherlands.
“As provided by relevant European legislation, third parties will have nine months from the issue date to oppose the patent in the EPO.”
Intellia Therapeutics CEO Nessan Bermingham said: “We are extremely pleased with this EPO outcome as it recognizes Jennifer Doudna, Emmanuelle Charpentier and their team as CRISPR/Cas9 pioneers, and also acknowledges the breadth of their original patent application.
“Intellia continues to build on the compelling preclinical data we have generated and to focus on the development of our pipeline of novel human therapeutics that will potentially transform the lives of patients with genetic diseases.”